Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
Sponsored by Neurocrine Biosciences
About this trial
Last updated 2 years ago
Study ID
Status
Type
Phase
Placebo
Accepting
Not accepting
Trial Timing
Ended 6 months ago
What is this trial about?
What are the Participation Requirements?
Key Inclusion Criteria:
- At least 18 years of age
- Have one of the following clinical diagnoses: schizophrenia or schizoaffective
disorder, bipolar disorder, or major depressive disorder
- Have a clinical diagnosis of neuroleptic-induced TD
- Medication(s) for schizophrenia or schizoaffective disorder, bipolar disorder, or
major depressive disorder and other protocol-allowed concurrent medications must be at
a stable dose and expected to remain stable during the study
- Participants must be outpatients and have a stable psychiatric status
Key Exclusion Criteria:
- Have comorbid abnormal involuntary movement(s) (for example, Parkinsonism, akathisia)
that is more prominent than TD
- Have an active, clinically significant unstable medical condition in the judgement of
the investigator, or have any laboratory value outside the normal range that is
considered by the investigator to be clinically significant at the screening visit